Structural and biologic characterization of pegylated recombinant IFN-alpha2b

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology
• Immunology

Background:

• Type I interferon-alpha (IFN-alpha) proteins possess significant anti-infective and antitumor properties.
• Interferon-alpha2b (Intron A) is a clinically utilized IFN-alpha2b protein.

Purpose of the Study:

• To develop a semisynthetic protein-polymer conjugate of IFN-alpha2b (Intron A) using monomethoxypolyethylene glycol (PEG-12000).
• To evaluate the structural integrity, biologic potency, and therapeutic activity of the pegylated interferon-alpha2b (PEG Intron).

Main Methods:

• PEGylation of IFN-alpha2b with PEG-12000 to create PEG Intron.
• Characterization using MALDI-MS, HPSEC, CD analysis, and tryptic digestion peptide analysis.
• In vitro assays including antiviral cytopathic protection, gene induction (2',5'-OAS, PKR), and immune response assays (NK and LAK cell activity).

Main Results:

• PEG Intron was found to be approximately 95% monopegylated with unaltered primary, secondary, and tertiary protein structures.
• PEGylation did not affect epitope recognition for Intron A quantitation.
• PEG Intron exhibited comparable molecular and cellular potency to Intron A in various in vitro assays, including antiviral and immunotherapeutic activities.

Conclusions:

• PEG Intron maintains the biologic potency profile of Intron A for both antiviral and immunotherapeutic activities.
• The PEGylation process enhances serum half-life, potentially prolonging patient exposure without compromising therapeutic efficacy.
• PEG Intron represents a promising therapeutic agent with potentially improved clinical utility compared to unmodified Intron A.